Limits...
Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse.

Ahmed F, Zafar HW, Buture A, Khalil M - Springerplus (2015)

Bottom Line: Chronic migraine affects 2 % of the population and has substantial impact on quality of life and considerable burden on healthcare resources. 50-80 % patients with chronic migraine have excessive consumption of analgesic medications.The data shows no difference in the therapeutic outcome in patients with or without analgesic overuse with substantial reduction in headache and migraine days and an increment in headache-free days in both groups in a real-life clinical setting.OnabotulinumtoxinA is equally effective in patients with chronic migraine with or without analgesic overuse.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ UK.

ABSTRACT
Chronic migraine affects 2 % of the population and has substantial impact on quality of life and considerable burden on healthcare resources. 50-80 % patients with chronic migraine have excessive consumption of analgesic medications. Withdrawal of analgesics is often advised before commencing preventive treatments. However, some headache experts recommend preventive treatments alongside analgesic withdrawal. 434 patients with chronic migraine attending the Hull Headache Clinic who received OnabotulinumtoxinA as preventive treatment were stratified to those with or without analgesic overuse. Data was collected through a dedicated headache diary and analysed for headache and migraine days reduction and for an increment in headache-free days in the month post treatment. The data shows no difference in the therapeutic outcome in patients with or without analgesic overuse with substantial reduction in headache and migraine days and an increment in headache-free days in both groups in a real-life clinical setting. OnabotulinumtoxinA is equally effective in patients with chronic migraine with or without analgesic overuse.

No MeSH data available.


Related in: MedlinePlus

Migraine days before and after treatment
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4628076&req=5

Fig3: Migraine days before and after treatment

Mentions: The results suggest no difference in reduction of headache or migraine days in the two groups. The changes in crystal clear (headache free days) were similar. Patients with medication overuse showed significant reduction in consumption of analgesics after treatment for both triptans and simple painkillers. However, these results should be set in the context of different pre-treatment values for painkiller days, with higher pre-treatment values for misusers than for non-misusers. Figures 2, 3, 4 illustrate the outcome on headache, migraine and headache free days in the two groups before and after treatment.Fig. 2


Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse.

Ahmed F, Zafar HW, Buture A, Khalil M - Springerplus (2015)

Migraine days before and after treatment
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4628076&req=5

Fig3: Migraine days before and after treatment
Mentions: The results suggest no difference in reduction of headache or migraine days in the two groups. The changes in crystal clear (headache free days) were similar. Patients with medication overuse showed significant reduction in consumption of analgesics after treatment for both triptans and simple painkillers. However, these results should be set in the context of different pre-treatment values for painkiller days, with higher pre-treatment values for misusers than for non-misusers. Figures 2, 3, 4 illustrate the outcome on headache, migraine and headache free days in the two groups before and after treatment.Fig. 2

Bottom Line: Chronic migraine affects 2 % of the population and has substantial impact on quality of life and considerable burden on healthcare resources. 50-80 % patients with chronic migraine have excessive consumption of analgesic medications.The data shows no difference in the therapeutic outcome in patients with or without analgesic overuse with substantial reduction in headache and migraine days and an increment in headache-free days in both groups in a real-life clinical setting.OnabotulinumtoxinA is equally effective in patients with chronic migraine with or without analgesic overuse.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ UK.

ABSTRACT
Chronic migraine affects 2 % of the population and has substantial impact on quality of life and considerable burden on healthcare resources. 50-80 % patients with chronic migraine have excessive consumption of analgesic medications. Withdrawal of analgesics is often advised before commencing preventive treatments. However, some headache experts recommend preventive treatments alongside analgesic withdrawal. 434 patients with chronic migraine attending the Hull Headache Clinic who received OnabotulinumtoxinA as preventive treatment were stratified to those with or without analgesic overuse. Data was collected through a dedicated headache diary and analysed for headache and migraine days reduction and for an increment in headache-free days in the month post treatment. The data shows no difference in the therapeutic outcome in patients with or without analgesic overuse with substantial reduction in headache and migraine days and an increment in headache-free days in both groups in a real-life clinical setting. OnabotulinumtoxinA is equally effective in patients with chronic migraine with or without analgesic overuse.

No MeSH data available.


Related in: MedlinePlus